Dr. Bauer on Rovalpituzumab Tesirine in SCLC

Todd Bauer, MD
Published: Monday, Oct 03, 2016



Todd Bauer, MD, associate director, Drug Development, Sarah Cannon Research Institute, discusses the emergence of the novel agent rovalpituzumab tesirine (Rova-T) in the treatment of patients with small cell lung cancer (SCLC) in an interview during the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.

SCLC, says Bauer, is one of the few cancers that is lacking in targeted therapies. Rova-T, specifically, targets DLL3, a molecule that is expressed in approximately two-thirds of patients with SCLC, making it an excellent marker in this space.

Currently, there are 3 ongoing studies assessing the efficacy of Rova-T. Beyond these trials, Bauer believes oncologists will soon look at Rova-T in a first-line setting, as well as in combination with immunotherapies such as nivolumab (Opdivo) and ipilimumab (Yervoy).


Todd Bauer, MD, associate director, Drug Development, Sarah Cannon Research Institute, discusses the emergence of the novel agent rovalpituzumab tesirine (Rova-T) in the treatment of patients with small cell lung cancer (SCLC) in an interview during the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.

SCLC, says Bauer, is one of the few cancers that is lacking in targeted therapies. Rova-T, specifically, targets DLL3, a molecule that is expressed in approximately two-thirds of patients with SCLC, making it an excellent marker in this space.

Currently, there are 3 ongoing studies assessing the efficacy of Rova-T. Beyond these trials, Bauer believes oncologists will soon look at Rova-T in a first-line setting, as well as in combination with immunotherapies such as nivolumab (Opdivo) and ipilimumab (Yervoy).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x